182 related articles for article (PubMed ID: 29782974)
21. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
[TBL] [Abstract][Full Text] [Related]
23. siRNA: Mechanism of action, challenges, and therapeutic approaches.
Alshaer W; Zureigat H; Al Karaki A; Al-Kadash A; Gharaibeh L; Hatmal MM; Aljabali AAA; Awidi A
Eur J Pharmacol; 2021 Aug; 905():174178. PubMed ID: 34044011
[TBL] [Abstract][Full Text] [Related]
24. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
25. RNA interference: the molecular immune system.
Bagasra O; Prilliman KR
J Mol Histol; 2004 Aug; 35(6):545-53. PubMed ID: 15614608
[TBL] [Abstract][Full Text] [Related]
26. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
De Paula D; Bentley MV; Mahato RI
RNA; 2007 Apr; 13(4):431-56. PubMed ID: 17329355
[TBL] [Abstract][Full Text] [Related]
27. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications.
Huang C; Li M; Chen C; Yao Q
Expert Opin Ther Targets; 2008 May; 12(5):637-45. PubMed ID: 18410245
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo evaluation of the efficacy of nanoformulation of siRNA as an adjuvant to improve the anticancer potential of cisplatin.
Koganti S; Jagani HV; Palanimuthu VR; Mathew JA; Rao MC; Rao JV
Exp Mol Pathol; 2013 Feb; 94(1):137-47. PubMed ID: 23064047
[TBL] [Abstract][Full Text] [Related]
29. Systemic delivery of siRNA by aminated poly(α)glutamate for the treatment of solid tumors.
Polyak D; Krivitsky A; Scomparin A; Eliyahu S; Kalinski H; Avkin-Nachum S; Satchi-Fainaro R
J Control Release; 2017 Jul; 257():132-143. PubMed ID: 27356019
[TBL] [Abstract][Full Text] [Related]
30. Oncogene suppression by small interfering RNAs.
Heidenreich O
Curr Pharm Biotechnol; 2004 Aug; 5(4):349-54. PubMed ID: 15320765
[TBL] [Abstract][Full Text] [Related]
31. Comparison of gene silencing in human vascular cells using small interfering RNAs.
Andersen ND; Monahan TS; Malek JY; Jain M; Daniel S; Caron LD; Pradhan L; Ferran C; Logerfo FW
J Am Coll Surg; 2007 Mar; 204(3):399-408. PubMed ID: 17324773
[TBL] [Abstract][Full Text] [Related]
32. Nanoformulation of siRNA silencing Bcl-2 gene and its implication in cancer therapy.
Jagani HV; Josyula VR; Hariharapura RC; Palanimuthu VR; Gang SS
Arzneimittelforschung; 2011; 61(10):577-86. PubMed ID: 22164966
[TBL] [Abstract][Full Text] [Related]
33. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.
Abbasi M; Lavasanifar A; Uludag H
Med Res Rev; 2013 Jan; 33(1):33-53. PubMed ID: 21523793
[TBL] [Abstract][Full Text] [Related]
34. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
35. Strategies for in vivo delivery of siRNAs: recent progress.
Higuchi Y; Kawakami S; Hashida M
BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
[TBL] [Abstract][Full Text] [Related]
36. siRNA--getting the message out.
Lee SH; Sinko PJ
Eur J Pharm Sci; 2006 Apr; 27(5):401-10. PubMed ID: 16442784
[TBL] [Abstract][Full Text] [Related]
37. RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice.
Wei J; Jones J; Kang J; Card A; Krimm M; Hancock P; Pei Y; Ason B; Payson E; Dubinina N; Cancilla M; Stroh M; Burchard J; Sachs AB; Hochman JH; Flanagan WM; Kuklin NA
Mol Pharmacol; 2011 Jun; 79(6):953-63. PubMed ID: 21427169
[TBL] [Abstract][Full Text] [Related]
38. Silencing or stimulation? siRNA delivery and the immune system.
Whitehead KA; Dahlman JE; Langer RS; Anderson DG
Annu Rev Chem Biomol Eng; 2011; 2():77-96. PubMed ID: 22432611
[TBL] [Abstract][Full Text] [Related]
39. Branched, tripartite-interfering RNAs silence multiple target genes with long guide strands.
Chang CI; Lee TY; Yoo JW; Shin D; Kim M; Kim S; Lee DK
Nucleic Acid Ther; 2012 Feb; 22(1):30-9. PubMed ID: 22221257
[TBL] [Abstract][Full Text] [Related]
40. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
